Business Standard

Bayer challenges cancer drug ruling favouring Natco

Patents office had allowed Natco to sell cheaper generic version of German firm's drug Nexavar

Read more on:    Bayer | Natco | Ipr | Nexavar | Cipla | Oncology | Cancer
Related News

Drugmaker has said that it is challenging an order from the patents office that allowed Hyderabad-based Pharma to sell a cheap generic version of the German firm's drug in India. Nexavar is used in the treatment of of the kidney and liver.

The patents office had stripped Bayer of its exclusive rights to sell Nexavar, saying most Indians could not afford it.

It told Natco Pharma to sell the generic drug significantly more cheaply and pay Bayer a 6% royalty on sales.

Bayer said it had appealed against the ruling.

"We will rigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients," a company spokesman said.

India's decision on Nexavar was seen as a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms.

Separately, Bayer is suing another Indian drugmaker, , for patent infringement over Nexavar. Cipla has been selling generic Nexavar in India and it has slashed the price of the drug by 75% to Rs 6,840 a month.

Read more on:   
|
|
|
|
|
|

Read More

CoalMin identifies 54 blocks for allocation through auction

Amid controversies over allegations of irregularities in allocation of coal mines, the Coal Ministry has identified 54 blocks to be allocated to ...


Quick Links

Back to Top